150 results on '"Feng, F.Y."'
Search Results
2. Prospective Characterization of Circulating Tumor Cells in Hormone Sensitive Oligometastatic Prostate Cancer Patients on a Metastasis-Directed Therapy Trial
3. Utility of PSMA PET Guided Metastasis-Directed Radiotherapy
4. FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP)
5. Prognostic Significance of Pretreatment Immune Cell Infiltration in Muscle Invasive Bladder Cancer Treated with Definitive Chemoradiation: Analysis of NRG RTOG 0524 and 0712
6. Identification of a Predictive Genomic Biomarker for Prostate Directed Therapy in Synchronous Low-Volume Metastatic Castration Sensitive Prostate Cancer
7. Impact of Testosterone Recovery on Clinical Outcomes of Patients Treated with Salvage Radiotherapy and Androgen Suppression: A Secondary Analysis of the NRG/RTOG 0534 Sport Phase 3 Trial
8. Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer
9. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels
10. Machine Learning for the Prediction of Distant Metastases Following Postprostatectomy Salvage Radiation Therapy
11. Machine Learning for the Prediction of Lymph Node Metastasis in Patients with Prostate Cancer
12. Challenges and Solutions during the COVID Pandemic for Patient Retention and Physician Engagement in the Phase 3 ATLAS Study of Apalutamide Added to Androgen Deprivation Therapy (ADT) in High-Risk Localized or Locally Advanced Prostate Cancer (HRLPC)
13. The Influence of Pelvic Lymph Node Dissection Volumes on Clinical Outcomes in NRG/RTOG 0534
14. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival Following Stereotactic Ablative Radiation Therapy in Oligometastatic Castration-Sensitive Prostate Cancer
15. INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer—Toxicity Update on First 213 Patients
16. Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology
17. Efficacy of Bicalutamide Monotherapy in Prostate Cancer: A Network Meta-Analysis of 10 Randomized Trials
18. Prognostic and Predictive Performance of a 24-Gene Post-Operative Radiation Therapy Outcomes Score (PORTOS) in a Phase 3 Randomized Trial of Dose-Intensified Salvage Radiotherapy after Radical Prostatectomy (SAKK 09/10)
19. Phase II Randomized Study of Salvage Radiation Therapy (SRT) plus Enzalutamide or Blinded Placebo for High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy: The SALV-ENZA Trial
20. Impact of cellularity and heterogeneity on deposited absorbed dose patterns of alpha and beta emitters in a model of tumoral clusters
21. Individual Patient Level Meta-Analysis of Prospective Trials Studying Metastasis-Directed Therapy for Metachronous Oligometastatic Prostate Cancer
22. Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer
23. Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials
24. Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126
25. Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer
26. Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer
27. Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics
28. NRG Oncology/RTOG 0926: Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
29. Utility of Long-Term Follow-Up to Determine Safety in Radiotherapy-Specific Trials for Localized Prostate Cancer: Meta-Analysis of 29 Randomized Trials
30. Model Selection for the Preclinical Development of New Drug–Radiotherapy Combinations
31. Metastasis-Free Survival, but Not Biochemical Failure, is a Strong Surrogate Endpoint for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601
32. Evaluating the Evidence to Support Clinical Use of the 22-Gene Genomic Classifier (Decipher) in Prostate Cancer
33. The Influence of the Pretreatment Host Immune State on Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521 (Updated)
34. Clinical-Genomic Sub-classification of High-Risk Prostate Cancer: Implications for Tailoring Therapy and Clinical Trial Design
35. Short-Term Adjuvant versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Randomized Phase 3 Trials
36. Comprehensive Analysis of Candidate Surrogate Endpoints in Localized Prostate Cancer: Analysis of 59 Randomized Trials
37. Effect Of Hormone Therapy Within Risk Groups Defined By Generalized Competing Event Model: Ancillary Analysis Of NRG Oncology’s RTOG 9408
38. Impact Of Sequencing Of Androgen Receptor-Signaling Inhibition (ARSI) And Ionizing Radiotherapy (RT) In Prostate Cancer: Importance Of Homologous Recombination (HR) Disruption
39. Association of Black Race With Improved Outcomes Following Definitive Radiotherapy With Androgen Deprivation Therapy for High-Risk Prostate Cancer: A Meta-Analysis of Eight Randomized Trials
40. The Impact of Persistently Elevated PSA after Prostatectomy in Men with Recurrent Prostate Cancer in NRG Oncology/RTOG 9601
41. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer
42. Timing of radiation after radical prostatectomy for men with prostate cancer may affect clinical outcomes
43. Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial
44. Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial
45. Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer
46. Associations of Stromal Infiltration with Prognosis and Response to Postoperative Radiotherapy in Prostate Cancer
47. External Beam Radiotherapy Plus Long-Term ADT Versus Combination Brachytherapy Plus Short-Term ADT for High Risk Prostate Cancer: A Network Meta-Analysis of Randomized Trials
48. Comparison of Population-Based Observational Studies to Randomized Controlled Trials in Prostate Cancer
49. Development and Validation of the First AJCC Compliant Clinical Staging System for Localized Prostate Cancer: Results from a Multicenter International Study
50. Transcriptomic Heterogeneity in Pathological Grade Group 5 Prostate Cancer: Implications for Biomarker Discovery
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.